Using AI to Accelerate Drug Discovery in Times of Crisis
During the COVID-19 pandemic, MozBioMed.AI led groundbreaking research to identify existing drugs that could be repurposed against the SARS-CoV-2 virus. This project combined artificial intelligence, computational biology, and big data analysis to accelerate the search for life-saving treatments at a critical time.
The Project
By leveraging AI algorithms and large-scale molecular databases, our research team screened thousands of known compounds to predict their effectiveness against COVID-19. This approach allowed us to prioritize the most promising candidates for further investigation — drastically reducing the time and cost of traditional drug development.
The project was spearheaded by Dr. Alexandre de Fátima Cobre, our founder, and has contributed significantly to the international scientific understanding of COVID-19 therapeutics.
Scientific Contribution
- Published in top-tier international journals, including the Journal of Biomolecular Structure and Dynamics and Computers in Biology and Medicine
- Identified potential inhibitors effective against emerging variants, such as Omicron
- Built a replicable AI pipeline for drug repurposing that can be applied to other diseases, including dengue and schistosomiasis
Impact
- Enabled faster response during a global health emergency
- Contributed to the WHO’s ongoing efforts in therapeutic strategies
- Laid the foundation for future AI-driven drug discovery initiatives focused on neglected diseases that lack commercial interest
What’s Next
We are now extending this AI methodology to support drug repurposing for:
- Neglected tropical diseases
- Emerging epidemics in Africa
- HIV and tuberculosis treatment optimization
This continued effort strengthens the case for African-led, AI-powered pharmaceutical innovation.
Contact
- 17 Longford Place, Manchester, England, M14 5QQ
- +44 7936 386026
- contact@mozbiomed.co.uk
